The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
|koncentrat proteolitičkih enzima obogaćenih bromelainom
|Type of prescription
|Summary of product characteristics (SmPC), labelling and package leaflet (PL)
|Link to the European Medicines Agency's (EMA) product information
|Link to the European Commission's (EC) decisions